What is the 13F Pro Quality Score for PFE?

13F Pro ranks PFIZER INC (PFE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PFE's current score at https://13fpro.ai/research/PFE (free sign-up required for the full ranking).

Which hedge funds own the most PFE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PFE include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PFE as soon as new 13F filings post.

Where does 13F Pro source PFE data?

All PFIZER INC fundamentals and ownership data come directly from SEC EDGAR. PFIZER INC files with the SEC under CIK 78003. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PFE in?

PFIZER INC (PFE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PFE's revenue?

Per PFIZER INC's latest 10-Q filed with the SEC on 2026-05-05, the biggest revenue drivers are: Biopharma ($14.2B, +5% YoY); Primary Care ($5.5B, -3% YoY); Oncology ($3.8B, +9% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/PFE.

What are PFE's largest expenses?

PFIZER INC's latest 10-Q reports these as the largest expense items: Cost of sales ($3.5B, +25% YoY); Research and development expenses ($2.5B, +13% YoY); Amortization of intangible assets ($1.2B, -2% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 29, 2026).

How often is PFE research updated on 13F Pro?

PFE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PFIZER INC(PFE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 78003 PFE stock profile & AI dashboard →

13F Pro Quality Score

69.0/100

Rank #389 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

31.2/100

Profitability

87.5/100

Balance Sheet

74.1/100

Earnings Quality

67.2/100

Free Cash Flow

66.4/100

Institutional Flow

73.2/100

Revenue Scale

97.6/100

Dilution Risk

50.9/100

PFE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PFIZER INC (PFE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PFE at 69.0/100 on a 32-signal composite quality model, placing it at rank #389 of 2,879 stocks — the top 25% of the AI-ranked universe. PFE scores in the top quartile across revenue scale (97.6), profitability (87.5). Areas of concern include revenue growth (31.2), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), PFIZER INC reports quarterly revenue of $14.5B, net income of $2.7B, free cash flow of $2.2B. Top institutional holders of PFE by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. PFE trades on the NYSE exchange and files with the SEC under CIK 78003. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PFE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PFIZER INC directly from SEC EDGAR. PFIZER INC's 13F Pro composite quality score has ranged between 8 and 90 since 2021, currently 69.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about PFIZER INC

Quirks, history, and lore behind PFE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on the NYSE · headquartered in New York City.
2
The Numbers
Annual revenue around $60 billion in a typical year, with an R&D budget that routinely tops $10 billion — because if your pill flops in Phase 3, that's a very expensive oops.
3
The History
Founded in Brooklyn in 1849 by a German-American chemist, it got its first big break supplying medicines to Union soldiers during the Civil War.
4
The Secret
It is one of the world's largest producers of penicillin and helped mass-produce it during World War II, arguably changing the outcome of the war one dose at a time.
5
The Lore
Its cholesterol drug Lipitor became the best-selling prescription drug in history, generating over $130 billion in lifetime sales — more than most countries' GDP.
6
The Giveaway
It partnered with BioNTech to deliver the world's first authorized mRNA COVID-19 vaccine in late 2020, shipping billions of doses in a race that the whole planet was watching.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PFE's Business? Latest 10-Q Breakdown

AI-extracted from PFIZER INC's 10-Q filed 2026-05-05 — Q1 2026 (quarter ended March 29, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Pfizer Q1 2026 revenues rose 5% to $14.5B, driven by strong growth in Padcev, Eliquis, and oncology biosimilars, partly offset by declining COVID-19 product sales.

Biggest Revenue Drivers

Total revenue: $14.5B+5% YoY

Biopharma$14.2B+5% YoY

Operational increase of 2% driven by Padcev, Eliquis, Oncology biosimilars, and Nurtec ODT/Vydura growth, offset by COVID-19 product decline.

Within Biopharma

Primary Care$5.5B-3% YoY

Decline primarily due to lower COVID-19 product revenues and lower Prevnar vaccination rates, partially offset by Eliquis growth.

Oncology$3.8B+9% YoY

Growth driven by Padcev strong uptake, Lorbrena increased market share, and Ibrance despite pricing pressure.

Specialty Care$2.9B+12% YoY

Growth primarily from Vyndaqel strong international demand and Xeljanz increased uptake.

Pfizer CentreOne$289M+6% YoY

Growth from higher manufacturing of third-party products and higher active pharmaceutical ingredient sales.

Largest Expense Items

Cost of sales$3.5B+25% YoY

Increase primarily due to non-recurrence of favorable 2025 royalty accrual revision and $285M unfavorable forex impact.

Research and development expenses$2.5B+13% YoY

Increase driven by $180M higher spending on certain oncology and obesity product candidates.

Amortization of intangible assets$1.2B-2% YoY

Restructuring charges and certain acquisition-related costs$100M-85% YoY

Decrease reflects lower restructuring activity versus prior year cost-reduction initiatives.

Margins: Gross margin declined as cost of sales increased 25% driven by non-recurrence of a favorable 2025 royalty revision and unfavorable foreign exchange, while revenues grew only 5%. Operating margin pressures were partially offset by lower restructuring charges and SG&A expense reductions from productivity improvements.

Watch Items from the Filing

Metsera acquisition of $8.0B completed November 2025 with contingent value rights up to $2.3B tied to development milestones; one-time integration costs expected ~$700M through 2027.
Patent exclusivity expirations expected to reduce revenues by ~$1.5B in 2026, with rate accelerating significantly 2026-2030 as multiple in-line products lose protection.
Eliquis benefited from 8% operational revenue growth but now faces Medicare Drug Price Negotiation Program negotiated price effective January 2026; Ibrance and Xtandi negotiated prices follow 2027-2028.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$14.5B

Net Income

Q1 2026

$2.7B

Free Cash Flow

Q1 2026

$2.2B

ROIC

Q1 2026

2.1%

D/E Ratio

Q1 2026

0.76

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.6% YoY

$62.58BFY 2025

FY22 $101.17BFY23 $59.55BFY24 $63.63BFY25 $62.58B

Net Income

-3.2% YoY

$7.77BFY 2025

FY22 $31.37BFY23 $2.12BFY24 $8.03BFY25 $7.77B

EPS (Diluted)

-3.5% YoY

$1.36FY 2025

FY22 $5.47FY23 $0.37FY24 $1.41FY25 $1.36

Total Assets

-2.5% YoY

$208.16BFY 2025

FY22 $197.21BFY23 $226.50BFY24 $213.40BFY25 $208.16B

Total Debt

-0.4% YoY

$67.79BFY 2025

FY22 $38.39BFY23 $74.14BFY24 $68.10BFY25 $67.79B

Op. Cash Flow

-8.2% YoY

$11.70BFY 2025

FY22 $29.27BFY23 $8.70BFY24 $12.74BFY25 $11.70B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$62.58B -1.6%	$63.63B +6.8%	$59.55B -41.1%	$101.17B +24.5%	$81.29B +98.7%	$40.91B
Net Income	$7.77B -3.2%	$8.03B +279.0%	$2.12B -93.2%	$31.37B +42.7%	$21.98B +37.1%	$16.03B
EPS (Diluted)	$1.36 -3.5%	$1.41 +281.1%	$0.37 -93.2%	$5.47 +42.1%	$3.85 +36.5%	$2.82
Total Assets	$208.16B -2.5%	$213.40B -5.8%	$226.50B +14.9%	$197.21B +8.7%	$181.48B +8.3%	$167.59B
Total Debt	$67.79B -0.4%	$68.10B -8.2%	$74.14B +93.1%	$38.39B -4.2%	$40.07B -25.3%	$53.61B
Operating Cash Flow	$11.70B -8.2%	$12.74B +46.5%	$8.70B -70.3%	$29.27B -10.2%	$32.58B +158.8%	$12.59B

AI Insight: PFE Financial Trends

Pfizer's profitability collapsed in Q4 2025 despite stable revenue and cash flow, signaling underlying operational stress.

• Net income swung from $3.5B profit in Q3 2025 to $1.6B loss in Q4 2025, then recovered to $2.7B in Q1 2026.

• Operating cash flow remained positive at $5.3B in Q4 2025 and $2.6B in Q1 2026, despite net loss.

• Total debt rose from $65.9B in Q3 2025 to $68.3B in Q1 2026, reversing prior deleveraging trend.

⚠ Q4 2025 net loss of $1.6B was unprecedented in this dataset; root cause and sustainability unclear.

⚠ Equity volatility: declined to $86.5B in Q4 2025, recovered to $90.1B in Q1 2026—signal of balance-sheet stress.

AI Insight: PFE Ratio Trends

Pfizer bounced back to 21.9% operating margin in Q1 2026 after a severe Q4 2025 collapse, but profitability metrics remain volatile and below 2024 peaks.

• Operating margin rebounded to 21.9% in Q1 2026 from -9.3% in Q4 2025, suggesting Q4 was a one-time charge or seasonal trough.

• ROIC stabilized at 8.0% in Q1 2026 vs. -4.3% in Q4 2025, recovering toward 2025 mid-year levels of 7.9%.

• Leverage improved slightly; D/E fell to 0.76 in TTM and Q1 2026 from 0.83 in Q2 2024, showing debt discipline.

⚠ Q4 2025 posted -9.3% operating margin and -7.6% ROE; root cause and recurrence risk unclear.

⚠ TTM metrics (12.5% OpMargin, 5.0% ROIC) lag Q1 2026 quarterly rates, suggesting ongoing earnings headwinds from prior quarters.

⚠ ROE and ROA remain below mid-2024 highs; Q1 2026 ROE 11.9% trails Q3 2025 peak of 15.3%.

Get alerted when PFE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PFIZER INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PFE

BlackRock, Inc.
$14.0B498,257,550 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.4B369,430,012 sh
STATE STREET CORP
$8.5B301,589,865 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.7B133,561,742 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$3.3B116,734,695 sh
Fisher Asset Management, LLC
$2.9B104,964,427 sh
MORGAN STANLEY
$2.6B92,685,370 sh
NORTHERN TRUST CORP
$1.7B62,026,552 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$1.6B56,911,830 sh
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO
$1.5B54,508,560 sh

Fund	Value	Shares
BlackRock, Inc.	$14.0B	498,257,550
VANGUARD CAPITAL MANAGEMENT LLC	$10.4B	369,430,012
STATE STREET CORP	$8.5B	301,589,865
GEODE CAPITAL MANAGEMENT, LLC	$3.7B	133,561,742
VANGUARD PORTFOLIO MANAGEMENT LLC	$3.3B	116,734,695
Fisher Asset Management, LLC	$2.9B	104,964,427
MORGAN STANLEY	$2.6B	92,685,370
NORTHERN TRUST CORP	$1.7B	62,026,552
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$1.6B	56,911,830
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	$1.5B	54,508,560

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PFE on your watchlist

Track score changes the day PFIZER INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PFE a good stock to buy?

13F Pro's AI-powered analysis of PFIZER INC (PFE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PFE are available on the PFE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PFE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PFE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PFIZER INC's investment landscape.